Preliminary Study Characterizing the Use of Sitagliptin for Glycemic Controlin Healthy Beagle Dogs with Normal Gluco-Homeostasis

Journal of Veterinary Medical Science

Peter LEE¹  Toshinori SAKO²  Hitomi ODA²  Kaori SAEKI²  Akihiro MORI²  Toshiro ARAI¹ 

[1] School of Veterinary Medicine, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1�?7�?1 Kyonancho, Musashino, Tokyo 180�?8602, Japan;School of Veterinary Nursing and Technology, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1�?7�?1 Kyonancho, Musashino, Tokyo 180�?8602, Japan

关键词: canine;    GIP;    GLP-1;    glucose;    insulin;    Sitagliptin;   

DOI  :  10.1292/jvms.13-0590

学科分类：兽医学

来源: Japanese Society of Veterinary Science

【 摘 要 】

References(35)Sitagliptin is a dipeptidyl peptidase-4 inhibitor aimed at treating Type 2 diabetesmellitus (T2DM) and T1DM, by increasing blood levels of Glucagon-like peptide 1 (GLP-1)and insulin. The objective of this preliminary study is to characterize Sitagliptin’sability for glycemic control, in healthy dogs under an oral glucose tolerance test (OGTT)environment. Overall, Sitagliptin did not result in any significant changes to temporalglucose and insulin concentrations. However, a ~55% increase in median total GLP-1AUC0�?120min was observed, as compared to baseline control in healthy dogs(n=5), thus indicating a similar mode of action of Sitagliptin between healthy dogs andhumans. Future studies to validate the use of Sitagliptin with dogs suffering from insulinindependent diabetes are warranted.

【 授权许可】

Unknown